An Evening of Diversity and Inclusion is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Wendy Nelson
CEO & President at Leading Biotech

Profile

Wendy Webber Nelson, PhD, is the CEO of LeadingBiotech, an event series that brings biopharma executives together through intimate and off-the-record collaborations, as well as President, Life Sciences Boston, for Informa Connect.  Wendy is also President & Founder of the Boston Biotech Forum and a Venture Partner for Waterman Ventures.

Wendy has nearly 20 years of business development, project management, operational, and R&D experience in biotechnology and large pharma companies, as well as in global CROs. Prior to assuming the CEO position at LeadingBiotech, Wendy was in business development roles of increasing responsibility for the past 10 years, most recently as the VP of Business Development, Marketing and Strategic Alliance for Frontage Laboratories. Prior to her roles in business development, Wendy was with Alantos Pharmaceuticals where she was responsible for Project Management and Operations of the two company programs and participated in many aspects of the post-merger integration following the $300M acquisition of Alantos by Amgen in 2007. She began her career in R&D at Alkermes, where she worked in formulations.

Wendy (WL Webber) is an inventor on multiple patents and patent applications, and is the senior author of a number of scientific publications. Wendy served several years on the organizational committees for both the Progeria Research Foundation and MIT Enterprise Forum.  She also participates in the MassCONNECT mentoring program through MassBio.  Dr. Nelson received her ScB and MS in Engineering and PhD in Medical Sciences all from Brown University.

Wendy Nelson's Network

Agenda Sessions

  • Introductory Remarks

    , 5:15pm